RESUMEN
INTRODUCTION: Hereditary hemorrhagic telangiectasia (HHT) is a rare disease with autosomal dominant inheritance that causes systemic vascular affectation. MATERIAL AND METHOD: After development a multicentric Spanish national registry, called RiHHTa, main clinical manifestations and diagnostic procedures of the first patients introduced are described. RESULTS: 141 patients were included, of which 91 (64.5%) were women. The mean age at diagnosis was 42 years. Mutations in the ACVRL1 gene predominated over the ENG gene. The initial symptom was recurrent epistaxis in 130 (92.2%) patients and in three (2.1%), brain abscess. Pulmonary arteriovenous (AV) fistula were detected in 36 (45%) of the 79 patients who underwent thoracic CT angiography. The contrast echocardiography detected very few bubbles (grade I) or none, in 36 (45%) of these 79 affected patients. In 43 (67.2%) of the 64 patients with an abdominal CT angiography, hepatic vascular malformations were detected, mostly telangiectasias, AV and arterio-portal fistula, and extrahepatic in 14 (10%) subjects. More than half of the patients were screened for the presence of brain arteriovenous malformations which was found in 3.9% of them. The upper part of the intestinal tube was the most (95%) affected region. CONCLUSION: The RiHHTa Registry allows improving the management of patients with HHT. An inadequate use of thoracic CT angiography and the usefulness of abdominal CT angiography has been detected in order to define subtypes of hepatic vascular involvement and detect extrahepatic vascular involvement.
RESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Polifarmacia , Isoniazida/uso terapéutico , Pirazinamida/uso terapéutico , Piridoxina/uso terapéutico , Paniculitis/complicaciones , Paniculitis/diagnóstico , Eritema Indurado/complicaciones , Eritema Indurado/diagnóstico , Síndrome de la Serotonina/complicaciones , Síndrome de la Serotonina/diagnóstico , Combinación de Medicamentos , Paroxetina/uso terapéutico , Monoaminooxidasa/uso terapéutico , Inhibidores de la Monoaminooxidasa/uso terapéutico , Rifampin/uso terapéuticoRESUMEN
No disponible